Complexities With SMN2 Copies in Spinal Muscular Atrophy: Basil Darras, MD

Video

The associate neurologist-in-chief at Boston Children’s Hospital discussed the 4-copy conundrum and whether treatment decisions differ based on SMN2 copies for patients with spinal muscular atrophy. [WATCH TIME: 2 minutes]

WATCH TIME: 2 minutes

"There was a committee convened by Cure SMA which has met a few times. During the last meeting, we voted in favor of treating babies with 4 copies of SMN2. That was published in a journal, but in spite of that, some insurance companies don’t even know about it or won’t take it into consideration."

Spinal muscular atrophy (SMA), a devastating neuromuscular disorder, is caused by low levels of the survival motor neuron (SMN) protein due to inactivating mutations in the encoding gene SMN1. A second duplicated gene, SMN2, produces little but sufficient functional protein for survival. Each of the 3 approved therapies for SMA increases the amount of full-length SMN protein; however, nusinersen (Spinraza; Biogen) and risdiplam (Evrysdi; Genentech) operate from SMN2, whereas AVXS-101 (Zolgensma; Novartis) produces the protein from SMN1.

AVXS-101, the only gene replacement therapy on the market, is approved for patients with type 1 SMA who have up to 3 SMN2 copies. The number of SMN2 copes was the first SMA modifier identified and is still the strongest known; however, the SMN2-copy number does not allow to precisely predict the course of the disease in a given individual. Clinicians within the space, including Basil Darras, MD, are still learning how to approach and treat infants with 4 copies of SMN2, otherwise known as the four-copy conundrum.

In a presentation given at the 2022 Cure SMA Clinical & Scientific Conference, June 15-17, in Anaheim, California, Darras provided an overview on the lingering questions with treating presymptomatic SMA and choosing the appropriate treatments. Darras, associate neurologist-in-chief at Boston Children’s Hospital, provided background on how the clinical community has approached infants with 4 SMN2 copies and whether treatment strategies change based on copy number.

Related Videos
Shadi Yaghi, MD, associate professor of neurology at Brown University
Matthew B. Harms, MD, MDA Medical Advisor and Care Center Director, Associate Professor of Neurology at Columbia University Irving Medical Center - Eleanor and Lou Gehrig ALS Center.
Ava L. Liberman, MD, medical director of the Stroke Center at Weill Cornell Medicine
Svetlana Blitshteyn, MD, FAAN, director and founder of Dysautonomia Clinic
Tudor Jovin, MD; Lauren Sansing, MD, MS, FAHA
© 2024 MJH Life Sciences

All rights reserved.